Clinical significance of baseline Epstein–Barr virus DNA for recurrent or metastatic primary pulmonary lymphoepithelioma-like carcinoma

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Bégin LR, Eskandari J, Joncas J, Panasci L. Epstein-Barr virus related lymphoepithelioma-like carcinoma of lung. J. Surg. Oncol. 36(4), 280–283 (1987). • First study reported the relationship primary pulmonary lymphoepithelioma-like carcinoma and Epstein–Barr virus (EBV).
  Medline CASGoogle Scholar
• 2. Ho JC, Lam DC, Wong MK et al. Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung. J. Thorac. Oncol. 4(9), 1174–1177 (2009).
  MedlineGoogle Scholar
• 3. Liang Y, Wang L, Zhu Y et al. Primary pulmonary lymphoepithelioma-like carcinoma: fifty-two patients with long-term follow-up. Cancer 118(19), 4748–4758 (2012). • A long-term follow-up for primary pulmonary lymphoepithelioma-like carcinoma.
  Medline CASGoogle Scholar
• 4. Castro CY, Ostrowski ML, Barrios R et al. Relationship between Epstein–Barr virus and lymphoepithelioma-like carcinoma of the lung: a clinicopathologic study of 6 cases and review of the literature. Hum. Pathol. 32(8), 863–872 (2001).
  Medline CASGoogle Scholar
• 5. Ho JC, Wong MP, Lam WK. Lymphoepithelioma-like carcinoma of the lung. Respirology 11(5), 539–545 (2006).
  MedlineGoogle Scholar
• 6. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC, Lyon, France (2004).
  Google Scholar
• 7. Travis WD, Brambilla E, Nicholson AG et al. The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J. Thorac. Oncol. 10(9), 1243–1260 (2015).
  MedlineGoogle Scholar
• 8. Nicholson AG, Tsao MS, Beasley MB et al. The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. J. Thorac. Oncol. 17(3), 362–387 (2022).
  MedlineGoogle Scholar
• 9. Huang CJ, Feng AC, Fang YF et al. Multimodality treatment and long-term follow-up of the primary pulmonary lymphoepithelioma-like carcinoma. Clin. Lung Cancer 13(5), 359–362 (2012).
  MedlineGoogle Scholar
• 10. Kumar V, Dave V, Harris J, Huang Y. Response of advanced stage recurrent lymphoepithelioma-like carcinoma to nivolumab. Immunotherapy 9(12), 955–961 (2017).
  CASGoogle Scholar
• 11. Qin Y, Gao G, Xie X et al. Clinical features and prognosis of pulmonary lymphoepithelioma-like carcinoma: summary of eighty-five cases. Clin. Lung Cancer 20(3), e329–e337 (2019).
  MedlineGoogle Scholar
• 12. Tang L, Chen N, He W et al. The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a systematic review and meta-analysis. PLOS ONE 15(10), e0240729 (2020).
  Medline CASGoogle Scholar
• 13. He J, Shen J, Pan H et al. Pulmonary lymphoepithelioma-like carcinoma: a Surveillance, Epidemiology, and End Results database analysis. J. Thorac. Dis. 7(12), 2330–2338 (2015).
  MedlineGoogle Scholar
• 14. Hong S, Liu D, Luo S et al. The genomic landscape of Epstein–Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat. Commun. 10(1), 3108 (2019). • Original article providing a comprehensive genomic landscape of primary pulmonary lymphoepithelioma-like carcinoma.
  MedlineGoogle Scholar
• 15. Chen B, Zhang Y, Dai S et al. Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses. Signal Transduct. Target Ther. 6(1), 6 (2021).
  Medline CASGoogle Scholar
• 16. Lin JC, Wang WY, Chen KY et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med. 350(24), 2461–2470 (2004).
  Medline CASGoogle Scholar
• 17. Liu LT, Tang LQ, Chen QY et al. The prognostic value of plasma Epstein–Barr viral DNA and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 93(4), 862–869 (2015).
  Medline CASGoogle Scholar
• 18. Ngan RK, Yip TT, Cheng WW et al. Circulating Epstein–Barr virus DNA in serum of patients with lymphoepithelioma-like carcinoma of the lung: a potential surrogate marker for monitoring disease. Clin. Cancer Res. 8(4), 986–994 (2002). • First study reported the clinical value of EBV DNA for primary pulmonary lymphoepithelioma-like carcinoma.
  MedlineGoogle Scholar
• 19. Xie M, Wu X, Wang F et al. Clinical significance of plasma Epstein–Barr virus DNA in pulmonary lymphoepithelioma-like carcinoma (LELC) patients. J. Thorac. Oncol. 13(2), 218–227 (2018). •• The prospective study about the clinical significance of baseline EBV DNA level for patients with stage I to IV primary pulmonary lymphoepithelioma-like carcinoma.
  Medline CASGoogle Scholar
• 20. Li QW, Qiu B, Hu WM et al. Plasma Epstein–Barr virus-deoxyribonucleic acid copy number predicts disease progression in stage I–III pulmonary lymphoepithelioma-like carcinoma. Front Oncol. 10, 1487 (2020).
  MedlineGoogle Scholar
• 21. Wei X, Wei Z, Zheng G et al. Prognostic significance of circulating Epstein–Barr virus DNA in pulmonary lymphoepithelioma-like carcinoma: a meta-analysis and validation study. J. Med. Virol. 95(1), e28349 (2023).
  Medline CASGoogle Scholar
• 22. Zou QH, Liu H, Huang CW et al. Efficacy and safety of gemcitabine and capecitabine combination for patients with previously treated advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective single-arm cohort study. Transl. Lung Cancer Res. 12(1), 96–108 (2023).
  Medline CASGoogle Scholar
• 23. Goldstraw P, Chansky K, Crowley J et al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J. Thorac. Oncol. 11(1), 39–51 (2016).
  MedlineGoogle Scholar
• 24. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
  Medline CASGoogle Scholar
• 25. Shao JY, Li YH, Gao HY et al. Comparison of plasma Epstein–Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer 100(6), 1162–1170 (2004).
  Medline CASGoogle Scholar
• 26. Chan MTV, Wang CY, Seet E et al. Association of unrecognized obstructive sleep apnea with postoperative cardiovascular events in patients undergoing major noncardiac surgery. JAMA 321(18), 1788–1798 (2019).
  MedlineGoogle Scholar
• 27. Ma H, Wu Y, Lin Y et al. Computed tomography characteristics of primary pulmonary lymphoepithelioma-like carcinoma in 41 patients. Eur. J. Radiol. 82(8), 1343–1346 (2013).
  MedlineGoogle Scholar
• 28. Qiu B, Lin YB, Cai QQ et al. Primary lymphoepithelioma-like carcinoma of ocular adnexa: clinicopathologic features and treatment. Curr. Oncol. 20(2), e113–e122 (2013).
  Medline CASGoogle Scholar
• 29. Ma H, Lin Y, Wang L et al. Primary lymphoepithelioma-like carcinoma of salivary gland: sixty-nine cases with long-term follow-up. Head Neck. 36(9), 1305–1312 (2014).
  MedlineGoogle Scholar
• 30. Pittaluga S, Wong MP, Chung LP, Loke SL. Clonal Epstein–Barr virus in lymphoepithelioma-like carcinoma of the lung. Am. J. Surg. Pathol. 17(7), 678–682 (1993).
  Medline CASGoogle Scholar
• 31. Chan AT, Lo YM, Zee B et al. Plasma Epstein–Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl. Cancer Inst. 94(21), 1614–1619 (2002).
  Medline CASGoogle Scholar
• 32. Wang ZY, Liu QF, Wang H et al. Clinical implications of plasma Epstein–Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood 120(10), 2003–2010 (2012).
  Medline CASGoogle Scholar
• 33. Qiu MZ, He CY, Lu SX et al. Prospective observation: clinical utility of plasma Epstein–Barr virus DNA load in EBV-associated gastric carcinoma patients. Int. J. Cancer 146(1), 272–280 (2020).
  Medline CASGoogle Scholar
• 34. Tan R, Phua SKA, Soong YL et al. Clinical utility of Epstein–Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma. Cancer Commun. (Lond) 40(11), 564–585 (2020).
  MedlineGoogle Scholar
• 35. Chen QY, Guo SY, Tang LQ et al. Combination of tumor volume and Epstein–Barr virus DNA improved prognostic stratification of stage II nasopharyngeal carcinoma in the intensity modulated radiotherapy era: a large-scale cohort study. Cancer Res. Treat. 50(3), 861–871 (2018).
  Medline CASGoogle Scholar
• 36. Ngan RK, Yip TT, Cheng WW et al. Clinical role of circulating Epstein–Barr virus DNA as a tumor marker in lymphoepithelioma-like carcinoma of the lung. Ann. N.Y. Acad. Sci. 1022(1), 263–270 (2004).
  Medline CASGoogle Scholar
• 37. Lin CY, Chang YC, Wang IT et al. Metabolic tumor volume predicts overall survival in patients with primary pulmonary lymphoepithelioma-like carcinoma. Oncol. Lett. 18(6), 6143–6149 (2019).
  Medline CASGoogle Scholar
• 38. Lin Z, Fu S, Zhou Y et al. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma. Lung Cancer 137, 100–107 (2019). • The research about the prognostic values of the first-line therapeutic regimens and EBV DNA for locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
  MedlineGoogle Scholar
• 39. Xiao Y, He J, Luo S et al. Comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: a retrospective study. Front Oncol. 12, 820302 (2022).
  Medline CASGoogle Scholar
• 40. Pang LL, Liao J, Huang YH et al. Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma. Int. J. Cancer 152(11), 2338–2350 (2023).
  Medline CASGoogle Scholar
• 41. Zhang X, Zhou Y, Chen H et al. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma. Front Immunol. 13, 1015444 (2022).
  Medline CASGoogle Scholar